HEALTH

Trump directs faster federal reviews of ibogaine research

▪

Read, Watch or Listen

Media Bias Meter

Sources: 5

Center 75%

Right 25%

Sources: 5

Washington — On Saturday, President Donald Trump signed an executive order directing the administration to accelerate federal reviews of certain psychedelic drugs, notably ibogaine, and to enable federally funded clinical research into their medical uses. The move follows growing veteran interest and private clinics abroad providing ibogaine treatments to Americans who currently travel for access. This action is intended to speed access to trials and research this year while maintaining ibogaine's Schedule I classification for now, according to federal reports. Immediate consequences include potential federal funding paths, statements of support from veterans and conservative lawmakers, and increased scrutiny of safety risks and regulatory oversight in coming months.

Prepared by Olivia Bennett and reviewed by editorial team.

Timeline of Events

Longstanding Schedule I designation restricts federal ibogaine research.
Veteran groups and private clinics expand cross-border ibogaine use.
Debate grows over potential therapeutic benefits versus safety risks.
President signs executive order to accelerate federal psychedelic reviews.
Agencies prepare protocols, funding routes, and safety oversight for trials.

Why This Matters to You

This order could fast-track research into ibogaine, a psychedelic drug, potentially unlocking new treatments for conditions like PTSD. If you or a loved one are seeking alternatives, keep an eye on clinical trials. But remember, ibogaine is still a Schedule I drug with safety risks.

The Bottom Line

Trump's order is a significant step towards exploring the medical potential of psychedelics. However, it doesn't change ibogaine's legal status. So, while research may accelerate, it's not a green light for unsupervised use. Worth forwarding if you know someone interested in alternative therapies.